Long‐term clinical outcomes of aspirin‐exacerbated respiratory disease: Real‐world data from an adult asthma cohort

Abstract

AbstractBackgroundAspirin‐exacerbated respiratory disease (AERD) is a phenotype of severe asthma, but its disease course has not been well documented compared with that of aspirin‐tolerant asthma (ATA).ObjectivesThis study aimed to investigate the long‐term clinical outcomes between AERD and ATA.MethodsAERD patients were identified by the diagnostic code and positive bronchoprovocation test in a real‐world database. Longitudinal changes in lung function, blood eosinophil/neutrophil counts, and annual numbers of severe asthma exacerbations (AEx) were compared between the AERD and the ATA groups. Within a year after baseline, two or more severe AEx events indicated severe AERD, whereas less than two AEx events indicated nonsevere AERD.ResultsAmong asthmatics, 353 had AERD in which 166 and 187 patients had severe and nonsevere AERD, respectively, and 717 had ATA. AERD patients had significantly lower FEV1%, higher blood neutrophil counts, and higher sputum eosinophils (%) (all p < .05) as well as higher levels of urinary LTE4 and serum periostin, and lower levels of serum myeloperoxidase and surfactant protein D (all p < .01) than those with ATA. In a 10‐year follow‐up, the severe AERD group maintained lower FEV1% with more severe AEs than the nonsevere AERD group.Conclusion and Clinical RelevanceWe demonstrated that AERD patients presented poorer long‐term clinical outcomes than ATA patients in real‐world data analyses.